• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

BMC Immunol . Methionine enkephalin(MENK) upregulated memory T cells in anti-influenza response

tetano

Editor, Senior Moderator
BMC Immunol


. 2023 Oct 12;24(1):38.
doi: 10.1186/s12865-023-00573-0. Methionine enkephalin(MENK) upregulated memory T cells in anti-influenza response

Jing Tian[SUP] 1 2 [/SUP], Wenrui Fu[SUP] 1 [/SUP], Zifeng Xie[SUP] 1 [/SUP], Xiaonan Wang[SUP] 3 [/SUP], Miao Miao[SUP] 3 [/SUP], Fengping Shan[SUP] 4 [/SUP], Xiaodong Yu[SUP] 5 [/SUP]



Affiliations
Abstract

Novel prophylactic drugs and vaccination strategies for protection against influenza virus should induce specific effector T-cell immune responses in pulmonary airways and peripheral lymphoid organs. Designing approaches that promote T-cell-mediated responses and memory T-cell differentiation would strengthen host resistance to respiratory infectious diseases. The results of this study showed that pulmonary delivery of MENK via intranasal administration reduced viral titres, upregulated opioid receptor MOR and DOR, increased the proportions of T-cell subsets including CD8[SUP]+[/SUP] T cells, CD8[SUP]+[/SUP] T[SUB]EM[/SUB] cells, NP/PA-effector CD8[SUP]+[/SUP] T[SUB]EM[/SUB] cells in bronchoalveolar lavage fluid and lungs, and CD4[SUP]+[/SUP]/CD8[SUP]+[/SUP] T[SUB]CM[/SUB] cells in lymph nodes to protect mice against influenza viral challenge. Furthermore, we demonstrated that, on the 10th day of infection, the proportions of CD4[SUP]+[/SUP] T[SUB]M[/SUB] and CD8[SUP]+[/SUP] T[SUB]M[/SUB] cells were significantly increased, which meant that a stable T[SUB]CM[/SUB] and T[SUB]EM[/SUB] lineage was established in the early stage of influenza infection. Collectively, our data suggested that MENK administered intranasally, similar to the route of natural infection by influenza A virus, could exert antiviral activity through upregulating T-cell-mediated adaptive immune responses against influenza virus.

Keywords: Antiviral efficacy; Influenza A virus; Memory T cell; Methionine enkephalin; Opioid receptor.

 
Back
Top Bottom